Blood test may help decide who gets second chance at targeted cancer therapy

NCT ID NCT07536113

Recruiting now Knowledge-focused Sponsor: Niguarda Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study looks at whether a liquid biopsy (ctDNA test) can help select metastatic colorectal cancer patients who might benefit from retreatment with anti-EGFR drugs. Researchers will collect data from 250 patients already screened in a prior trial. The goal is to see if ctDNA status predicts treatment success in a real-world setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-EGFR therapy (rechallenge)
What this could lead to: If successful, this study could show that ctDNA testing helps doctors decide which patients with metastatic colorectal cancer might benefit from retreatment with anti-EGFR drugs.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients, and the approach may not improve outcomes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (CRC)

Contacts and locations

Locations

ASST GOM Niguarda
RECRUITING

Milan, Italia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.